Moleculin Gears Up for IPO
Moleculin Biotech plans to list up to 2 million shares at an estimated $5.50 apiece in an IPO valued at up to $11 million.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 220
Why Investors Still Like Celator Pharma Despite a Loss
Celator Pharmaceuticals reported its fourth-quarter financial results before the markets opened on Monday.
Advaxis Soars on Positive Survival Results
Advaxis made waves in the markets on Monday following the release of positive data from its most recent study.
Why GW Pharma Could More Than Double From Cannabinoid Drugs
What are investors supposed to make of a Bank of America Merrill Lynch call that shows GW Pharmaceuticals worth over 100% more than the current value?
BioMarin Sinks Despite Meeting Primary Endpoint
BioMarin Pharmaceutical made waves early Monday following the release of late-stage results from its pegvaliase study.
How Analysts View Valeant After an Earnings Catastrophe
Releasing preliminary results may have been ill-advised to release, as the impact was absolutely catastrophic to Valeant Pharmaceuticals stock.
4 Key Biopharma Movers of the Past Week
Over the past week, Celator Pharmaceuticals and a few other biotech companies made impressive runs.
Pfizer Posts Positive Late-Stage Results in Colitis Trials
Pfizer announced the results from its first two pivotal Phase 3 studies from the Oral Clinical Trials for tofacitinib in ulcerative colitis program at the 11th Congress of European Crohn's and Colitis Organization.
4 Well-Known Health Care Stocks Are Potential Buyout Candidates
With an aging population, and larger health care companies looking to add new technologies and capabilities, the chances for mergers and acquisitions activity to jump are very real.
Why Eagle Pharma Shares Are in Free Fall
Eagle Pharmaceuticals shares were in free fall early Friday after it received a Complete Response Letter from the FDA for its Kangio.
Hutchinson China MediTech Sets Price for US IPO
Hutchinson China MediTech will offer more than 7 million American depositary shares at $13.50 apiece in and IPO valued at up to more than $116 million.
Could This Be the Big Comeback for Vitae Pharma?
Vitae Pharmaceuticals watched its shares absolutely take off on Thursday morning following the release of positive results from its mid-stage clinical trial.
Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict
Regeneron Pharmaceuticals saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen on a cholesterol drug patent.
4 More Key FDA Decisions in March
24/7 Wall St. has collected a few more U.S. Food and Drug Administration (FDA) decisions coming up in March.
Why One Analyst Sees Gilead Worth 66% More
Argus reiterated Gilead Sciences as Buy, but hat really matters here is that Argus has a $150 price target on the stock.